Insulin data from Novo Nordisk connected pens to be combined with Roche’s data for digital diabetes management.

Roche Diabetes Care has established an open ecosystem, connecting devices and digital solutions to enable optimal personalized diabetes management and improved therapy outcomes. Through a recently announced collaboration with Novo Nordisk, it plans to further expand access to therapy information. 

The new collaboration builds on an “ongoing and successful partnership between the two companies,” according to Anders Toft, Corporate Vice President of Commercial Innovation at Novo Nordisk. In this latest development and collaboration agreement, the companies have committed to integrating insulin data from Novo Nordisk's connected pen to Roche's open ecosystem, synchronizing with its suite of digital diabetes management solutions including mySugr.

According to Roche, diabetes self-care takes on average one hour each day, and people with diabetes have to make up to 50 therapy decisions on a daily basis. “Digital health solutions have the potential to ease this constant burden and as such to support better therapy adherence and improved outcomes,” it said in a press release.

The partners believe that integration of insulin pen data into Roche’s mySugr digital solution will make it easier for people with diabetes and their caregivers to track the effect of insulin on blood glucose levels, enabling more efficient and targeted decision support. “By integrating Novo Nordisk connected technology with mySugr, we can further ease the day-to-day burden of disease management and provide data-based insights to improve the dialogue between patients and caregivers," said Toft.